Amgen’s dazodalibep Phase 3 trial clears Sjögren’s hurdle
Amgen (AMGN) reported that its Phase 3 trial for dazodalibep met its primary endpoint in treating moderate-to-severe systemic Sjögren’s disease, showing statistically significant improvement. The study enrolled 651 participants, and the drug is currently under review. Amgen's revenue was $10.054 billion in Q2 2026, with net income of $2.375 billion. A second Phase 3 trial, OASIZ 303, is expected to complete in Q4 2026.
How this was made
The 30-second read
Why it matters
The data could unlock a new revenue stream for Amgen and influence valuation multiples for similar biotech candidates.
Market read
Positive trial data is a catalyst for AMGN and may ripple through the autoimmune biotech space.
What to watch
Amgen's cash position may fund further trials, but the upcoming OASIZ 303 readout could temper expectations if results are less robust.
Background
Amgen's dazodalibep trial is the first positive late‑stage readout for systemic Sjögren’s disease, a condition with no approved therapy.
Ticker impact
Amgen announced its dazodalibep Phase 3 trial met the primary endpoint in systemic Sjögren’s disease, sending the stock higher.
upward pressure on AMGN over the next few trading days
First‑time disclosure of statistically significant efficacy, combined with short‑interest decline, suggests fresh buying interest.
Market effects
Strengthens the biotech pipeline narrative and may boost peer biotech stocks focused on autoimmune therapies.
Positive for US biotech sector; limited immediate impact outside the US.
Highlights continued innovation in rare disease treatments, relevant to global investors tracking biotech pipelines.
Counterpoint
If regulatory review stalls or later data disappoint, the rally could reverse; investors should watch FDA filing timeline.
Key entities
- companyAmgen
US‑listed biotech/pharma company reporting the trial result.
- drugdazodalibep
Investigational antibody targeting Sjögren’s disease.
